Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control.
A J Scheen1, N Esser2, N Paquot2
1Clinical Pharmacology Unit, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège and Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU de Liège, CHU Sart Tilman (B35), 4000 Liège 1, Belgium.
Diabetes & Metabolism
|March 22, 2015
Summary
Chronic inflammation is linked to type 2 diabetes and its complications. Some glucose-lowering drugs, like metformin and thiazolidinediones, show anti-inflammatory effects beyond blood sugar control, potentially improving patient outcomes.
Area of Science:
- Endocrinology
- Pharmacology
- Immunology
Background:
- Chronic inflammation is closely linked to abdominal obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease.
- Understanding these links is crucial for developing new therapeutic strategies targeting silent inflammation.
Purpose of the Study:
- To review the anti-inflammatory effects of various glucose-lowering medications used in managing type 2 diabetes.
- To differentiate between anti-inflammatory effects due to improved glycemic control and intrinsic drug actions.
Main Methods:
- Review of existing scientific literature on glucose-lowering agents and their impact on inflammatory markers.
- Analysis of studies focusing on metformin, thiazolidinediones (TZDs), sulfonylureas, glinides, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter type 2 (SGLT2) inhibitors, and insulin.
Main Results:
- Metformin and TZDs demonstrate significant anti-inflammatory activity, potentially greater than insulin secretagogues.
- TZDs show extensive evidence for reducing both tissue and serum inflammation.
- Incretin-based therapies (DPP-4 inhibitors and GLP-1 receptor agonists) show promising anti-inflammatory potential, while alpha-glucosidase inhibitors have modest effects.
- SGLT2 inhibitors' systemic anti-inflammatory activity is not yet established in humans.
- Exogenous insulin may also possess anti-inflammatory properties.
Conclusions:
- Certain glucose-lowering agents possess intrinsic anti-inflammatory properties that may contribute to improved outcomes in diabetic patients.
- Distinguishing between glucose-lowering effects and direct anti-inflammatory actions is critical for clinical application.
- Further research is needed to clarify the role of these anti-inflammatory effects in preventing diabetic macrovascular and microvascular complications.
Keywords:
GLP-1 receptor agonistGliptinInflammationMetforminThiazolidinedioneType 2 diabetes mellitusMore Related Videos
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
11.0K
08:47Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
10.4K
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
909
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
909
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
989
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
989
01:06Oral Hypoglycemic Agents: Glinides
995
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:24Glucagon-like Receptor Agonists
1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K